The primary objective of the study was to determine if we could independently identify GPC3 expression in pancreatic cancer in a significant proportion of patients in our Canadian patient population with the antibody protocol we currently use in diagnostic pathology practice. This evidence concerns the gene GPC3 and familial pancreatic carcinoma.